Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cabozantinib + pembrolizumab
- Development stage
- Phase 2
- Lead developer
- Exelixis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Cabozantinib + pembrolizumab is a combination regimen consisting of cabozantinib, a multi-targeted tyrosine kinase inhibitor, and pembrolizumab, an anti–PD-1 monoclonal antibody immune checkpoint inhibitor. Cabozantinib targets multiple tyrosine kinases, including MET, VEGFR-2, RET, AXL, and FLT-3, inhibiting tumor angiogenesis, cell proliferation, and metastasis, and modulating the tumor microenvironment. Pembrolizumab blocks the PD-1 receptor on T-cells, thereby restoring antitumor immune response. Their use in combination is under investigation and has shown promising antitumor activity and manageable safety in several cancer types, including metastatic renal cell carcinoma, ICI-resistant gastroesophageal adenocarcinoma, and advanced sarcomas[1][2][3][4][5][7].
- Other names
- pembrolizumab + cabozantinib
02
Targets
AXL (AXL receptor tyrosine kinase)FLT3 (Fms related receptor tyrosine kinase 3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)MET (Mesenchymal-epithelial transition factor receptor)PDCD1 (Programmed cell death protein 1 receptor)RET (Rearranged during transfection receptor tyrosine kinase)TEK (Tie2)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on cabozantinib + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cabozantinib + pembrolizumab.